This clinical trial is studying two conditions called Rheumatoid Arthritis and Psoriatic Arthritis. These are long-term conditions where the body’s immune system mistakenly attacks the joints, causing pain, swelling, and stiffness. The treatment being tested involves combining two types of biologic drugs that work in different ways to control inflammation. Patients in the study will continue taking their current Tumour Necrosis Factor inhibitor medication, which is a type of biologic drug that blocks a protein in the body that causes inflammation. To this existing treatment, a second medication called tocilizumab will be added. Tocilizumab is given as an injection under the skin using a pre-filled pen and works by blocking a different protein called interleukin-6 that also contributes to inflammation and joint damage.
The purpose of this study is to find out whether combining these two different biologic medications is safe and whether it works better at controlling disease activity than current treatments alone. The study will specifically measure how many patients achieve remission, which means their disease becomes much less active or shows minimal signs of inflammation. The researchers want to test whether blocking two different inflammation pathways at the same time can help more patients reach this state of very low disease activity.
During the study, patients will receive the combination treatment for a period of time while their disease activity is regularly monitored. The main assessment will take place at week 24 to see how well the combination therapy has worked. Throughout the study, doctors will also carefully watch for any side effects or safety concerns that might occur when using these two medications together. The study will collect information about how well patients tolerate the combination treatment and whether their symptoms improve according to standard measurement tools used to assess arthritis activity.
Spain 
